ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
11 sept. 2019 09h28 HE
|
Schall Law
LOS ANGELES, Sept. 11, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
04 sept. 2019 11h30 HE
|
Schall Law
LOS ANGELES, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
27 août 2019 12h03 HE
|
Schall Law
LOS ANGELES, Aug. 27, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
21 août 2019 11h50 HE
|
Schall Law
LOS ANGELES, Aug. 21, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG...
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
02 juil. 2019 08h31 HE
|
InveniAI
Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...
Poseida Therapeutics Raises $142 Million in Series C Financing
22 avr. 2019 07h00 HE
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
Cambia Health Solutions hires Alison Esquea as Vice President of Federal Affairs
21 févr. 2019 08h04 HE
|
Cambia Health Solutions
PORTLAND, Ore., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cambia Health Solutions is pleased to announce that the Public Affairs and Policy team has hired Alison Esquea as Vice President of Federal Affairs,...
Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
20 nov. 2018 09h00 HE
|
Alzamend Neuro, Inc.
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...
Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor
09 déc. 2015 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland , Dec. 09, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announced today that they have entered into an exclusive, worldwide license agreement with Novartis for...
Pharmaceutical Executive Joins Mesoblast As Chief Financial Officer
24 août 2014 21h16 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 24, 2014 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as...